Clinical observation of continuous treatment with almonertinib after treatment with osimertinib in EGFR mutation positive advanced NSCLC patients with drug resistance

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100049904

Enrollment

Unknown

Registered

2021-08-10

Start date

2021-08-15

Completion date

Unknown

Last updated

2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Interventions

case series:Almonertinib 110 mg orally,once a day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Eligible patients are 19 years old or older; 2. Histologically diagnosed as metastatic or recurrent NSCLC; newly diagnosed EGFR mutation positive; 3. The T790M mutation was detected after the first-line/second-generation TKI was used for resistance; the second-line application of osimertinib showed slow progress; 4. ECOG score of 2 and below; no obvious abnormality in the evaluation of organ and bone marrow function.

Exclusion criteria

Exclusion criteria: Previous use of almonertinib; A history of interstitial lung disease; Active infections requiring systemic treatment; Or uncontrolled brain metastases; Past use of pirated TKI drugs.

Design outcomes

Primary

Measure	Time frame
objective response rate;progression-free survival;overall survival;	—

Secondary

Measure	Time frame
response time;safety;	—

Countries

China

Contacts

Public ContactZhu Yuxi

The First Affiliated Hospital of Chongqing Medical University

zhuyuxi@hospital.cqmu.edu.cn+86 15823595945

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026